Dataset: Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats ----------------------------------------------------------------------- **Abstract** Alzheimer's disease (AD) is characterized pathologically by the presence of amyloid plaques and neurofibrillary tangles. The amyloid hypothesis contends that the abnormal accumulation of Aβ, the principal component of amyloid plaques, plays an essential role in initiating the disease. Impaired clearance of soluble Aβ from the brain, a process facilitated by apolipoprotein E (APOE), is believed to be a contributing factor in plaque formation. APOE expression is transcriptionally regulated through the action of a family of nuclear receptors including the peroxisome proliferator-activated receptor gamma and liver X receptors (LXRs) in coordination with retinoid X receptors (RXRs). It has been previously reported that various agonists of this receptor family can influence brain Aβ levels in rodents. In this study we investigated the effects of LXR/RXR agonism on brain and cerebrospinal fluid (CSF) levels of Aβ40 in naïve rats. Treatment of rats for 3 days or 7 days with the LXR agonist, TO901317 or the RXR agonist, Bexarotene did not result in significant changes in brain or CSF Aβ40 levels. Read the [full-text][1] publication by Wang, Wen, and Wood (*F1000Research*, 2016) for more details. **Data availability** [APOE – Bex 3d brain: Western blot of APOE in brain homogenate following 3 days treatment with Bexarotene. Actin is also included as a loading control.][2] [APOE – Bex 3d CSF: Western blot of APOE in CSF following 3 days treatment with Bexarotene.][3] [APOE – Bex 7d brain: Western blot of APOE in brain homogenate following 7 days treatment with Bexarotene. Actin is also included as a loading control.][4] [APOE – Bex 7d CSF: Western blot of APOE in CSF following 7 days treatment with Bexarotene.][5] [APOE – TO901317 3d brain: Western blot of APOE in brain homogenate following 3 days treatment with TO901317. Actin is also included as a loading control.][6] [APOE – TO901317 3d CSF: Western blot of APOE in CSF following 3 days treatment with TO901317.][7] [APOE – TO901317 7d brain: Western blot of APOE in brain homogenate following 7 days treatment with TO901317. Actin is also included as a loading control.][8] [APOE – TO901317 7d CSF: Western blot of APOE in CSF following 7 days treatment with TO901317.][9] [Bexarotene and TO901317 Study Data: Raw data and statistical analysis of APOE and Aβ analysis in brain and CSF following 3 and 7 days treatment with Bexarotene and TO901317. Aβ analysis in brain and CSF following treatment with a BACE inhibitor (AMG8155) is also included as a positive control.][10] [1]: http://dx.doi.org/10.12688/f1000research.7868.1 [2]: https://osf.io/bcedq/ [3]: https://osf.io/bg97q/ [4]: https://osf.io/txkes/ [5]: https://osf.io/thx5s/ [6]: https://osf.io/k2xer/ [7]: https://osf.io/a5bpn/ [8]: https://osf.io/wy3u7/ [9]: https://osf.io/sc5dh/ [10]: https://osf.io/u9p5a/